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A Randomised Comparison of 
Darbepoetin alfa with Epoetin for 
Chemotherapy Induced Anaemia in 
Nonhaematological Tumours
Aekaterini A. Kotsori, Costas G. Alexopoulos
A B S T R A C T
BACKGROUND: Although once weekly (QW) Darbepoetin is nowadays used by many 
for chemotherapy induced anaemia, a head to head comparison with thrice weekly 
(TIW) Epoetin regimen has not been published so far.
PATIENTS AND METHODS: We randomly compared weekly (QW) darbepoetin alfa 
with thrice weekly (TIW) Epoetin in 50 cancer patients with chemotherapy induced 
anaemia (Hb ≤11gr%). In Group A, Epoetin was administered at 10.000 U TIW 
(20.000 U in non-responders after 4 weeks). In Group B, Darbepoetin alfa was ad-
ministered at 150mcg QW (300 mcg as above). Evaluation, including QOL assessment 
using FACT-An scale, was performed on week 4 and 8. 
RESULTS: In group A, Hb increased from 9.81±1.02 at baseline to 10.59±1.38 at 4 
weeks (p=0.007) and to 11,4±1,99 at 8 weeks (p=0.001). It also increased between 
week 4 and 8 (p=0.011). In group B, Hb increased from 10,2±0,87 at baseline to 
10,8±1,93 at 4 weeks (p=0.075) and to 11.57±2.26 at 8 weeks (p=0.005) without 
significant increase between week 4 and 8 (p=0.08). In all 50 patients, Hb increased 
from 10.01±0.97 at baseline to 10.75±1.69 at 4 weeks (p=0.003) and to 11.49±2.11 at 8 
weeks (p=0.000). It also increased from 10.84±1.74 to 11.49±2.11 (p=0.003) between 
week 4 and 8. Twelve of 25 patients (48%) in group A had to double the Epoetin dose 
versus 13 (52%) in group B (P=NS). Three patients in group A required transfusions 
compared with 4 in group B (p=NS). On an intent-to-treat analysis: RR, at 4 weeks, 
was 44% for Epoetin versus 44% for Darbepoetin (p=NS). At 8 weeks, it was 48% and 
60%, respectively (p=NS). QOL analysis unexpectedly showed that fatigue and emo-
tional scores were worse in Group B than in Group A. Whether this, not easily explain-
able observation, is just an incidental finding remains to be shown in larger series.
CONCLUSIONS: QW Darbepoetin is a convenient therapy and it induced haemoglobin 
changes of similar magnitude to TIW Epoetin.
I N T R O D U C T I O N
The incidence of anaemia in cancer patients receiving chemotherapy varies be-
tween 35% and 95%, depending upon the tumor type, timing and chemotherapeutic 
regimen used [1-3]. There is an increasing understanding of the symptoms of anaemia 
and their impact on the lives of patients with cancer. Furthermore, anaemia has been 
recognized as a poor prognostic factor for survival in many malignancies [4-6].
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Recombinant human erythropoietin (Epoetin) is effec-
tive in treating chemotherapy induced anaemia and its ef-
fectiveness in improving quality of life and fatigue level has 
been confirmed in a randomized, placebo-controlled clinical 
trial [7]. The recommended starting regimen is 150U/Kg or 
a fixed dose of 10.000 U given subcutaneously, thrice weekly 
(TIW), which can be increased to 20.000 U thrice weekly if 
no response in haemoglobin level is observed after 4 weeks 
of treatment.
Despite the logic in using erythropoietic therapy for cancer 
related anaemia, there is evidence that not infrequently anae-
mic patients do not receive Epoetin until their haemoglobin 
level has dropped as low as 9 g/dl [8]. This current low rate of 
treatment with Epoetin is due to several factors including cost 
of therapy, lack of perception of the importance of anaemia 
by many oncologists and the relatively high degree of non 
response to therapy. The inconvenience of the indicated ad-
ministration schedule for Epoetin might be another factor. 
Recently, a less frequent dosing of Epoetin, namely once-
weekly, has been found to be effective therapy although an 
increase in the dose by 33% compared with the registered 
dosing recommendations was required [9]. These results have 
led many oncologists in Europe and USA to adopt the weekly 
schedule in their clinical practice. 
Darbepoetin alfa, a recombinant product characterized 
by the presence of two additional carbohydrate site chains, 
although it stimulates erythropoiesis by the same mechanism 
as endogenous erythropoietin and Epoetin, it demonstrates 
an extended half life in the body [10]. Despite the fact that the 
additional N-glycosylation results in a lower receptor binding 
capacity and a lower in vitro biological activity [11], Darbe-
poetin alfa demonstrates a greater in vivo biological activity 
than Epoetin [10,11].
There is now enough evidence that once-weekly (QW) 
administration of Darbepoetin is an effective treatment of 
chemotherapy induced anaemia [12-14]. Ôhe scheme has been 
recently used by many oncologists [15,16] nevertheless a head 
to head comparison with TIW Epoetin regimen has not been 
published so far.
We, therefore, decided to compare, in a prospective 
randomized study, the effectiveness of QW Darbepoetin alfa 
with TIW Epoetin.
S T U D Y  A I M
In the present study, we aimed to randomly compare the 
overall effectiveness of QW with TIW Epoetin. To achieve 
this purpose we set out:
• To compare the magnitude of haemoglobin changes from 
baseline to weeks 4 and 8, between patients treated with 
Darbepoetin alfa and those treated with Epoetin;
• To compare the needs for red blood cell transfusion, during 
chemotherapy, between the two groups of patients;
• To compare the impact of the two erythropoetins on the 
quality of life of the patients;
P A T I E N T S  A N D  M E T H O D S
Patients: Inclusion and Exclusion criteria are shown in 
table 1.
Laboratory investigations: Detailed pre-randomisation 
tests performed in all eligible patients and follow-up investiga-
tions are included in table 2. 
S T U D Y  D E S I G N  A N D  S T U D Y  D R U G S
This was a phase III, open-label study in which eligible 
patients were randomized in two groups:
Group A Patients received Epoetin 10.000 U thrice weekly. 
If an increase in Hb of 1.5 gr/dl was not observed after 4 
weeks, the dose was increased up to 20.000 U. If a <1.5gr/dl 
increase was observed after 4 weeks of titrating up the dose, 
Epoetin was discontinued.
Group B Patients received Darbepoetin alfa 150 mcg once 
weekly. If an incease in hemoglobin 1.5 gr/dl was not observed 
after 4 weeks, the dose was increased up to 300mcg. If a <1.5 
gr/dl increase was observed after 4 weeks of titrating up the 
dose, Darbepoetin was discontinued.
In both groups, when Hb reached the level of 13.5 gr/dl, 
TABLE 1. Inclusion and Exclusion criteria
Inclusion criteria Exclusion criteria
 - Age ≥18 years - Iron, B12 or Folate deficiency
 - Solid tumours only - Bleeding or haemolysis
 - Life expectancy of 4 months - Serum ferritin 10ng/ml
 - Scheduled to receive cyclic chemotherapy for at least 12 weeks - More than two RBC transfusions within 4 wks of randomisation
 - Hb level of 11gr/dl or less  or any within 16 days
 - Decrease of Hb ≥1.5gr /dl during chemotherapy - Epoetin therapy within 8 weeks
 - ECOG 0-3 - Uncontrolled hypertension
 - Serum creatinine ≤2mg/dl - Active infection
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the dose of erythropoetin was titrated as follows: for Darbe-
poetin, the effective weekly dose was given every two weeks, 
whereas for Epoetin the effective thrice weekly dose was given 
once weekly.
In both groups, patients with a ferritin level <20ng/ml 
received oral iron supplementation.
Red blood cell transfusion was allowed at any time during 
chemotherapy if Hb dropped to 8.5 gr/dl.
E F F I C A C Y  A S S E S S M E N T
Evaluation was performed at weeks 4 and 8. The following 
end points were assessed: 
1 .  H A E M O G L O B I N  R E S P O N S E :  
Complete response was defined as an increase in Çâ of 
1.5 gr/dl over baseline in the absence of blood transfusion 
in the preceding 28 days.
Partial response was defined as an increase between 1 
gr/dl and 1.4 gr/dl.
No response was defined as no increase or an increase of 
<1 gr/dl.
2 .  C H A N G E S  I N  H A E M O G L O B I N  L E V E L  O N  
W E E K  4  A N D  W E E K  8
3 .  Q U A L I T Y  O F  L I F E :
The FACT-An questionnaire was completed by the pa-
tients at baseline, week 4 and week 8.
S T A T I S T I C A L  C O N S I D E R A T I O N S
Analysis was performed on an intent-to-treat basis, and 
included all patients who received at least one dose of the 
study drug.
Changes in Çâ level are expressed as a mean ± SD. 
Comparison of the means was performed using the Paired-
Samples T test.
Comparative analysis of Hb response rate to erythropoetic 
therapy between groups was performed using Pearson Chi- 
square test. The same test was used in comparing the needs for 
blood transfusions and of doubling the dose of erythropoetin 
during the study period.
The impact of haemoglobin changes on quality of life was 
studied using the Functional Assessment of Cancer Thera-
py-Anaemia (FACT-An) scale [16]. The FACT-An scale is 
composed of the FACT-F plus seven additional non-fatigue 
items. The FACT-F is composed of the FACT-G (physical, 
emotional, social and functional well-being) plus the Fatigue 
subscale. Data were initially analysed to determine internal 
consistency (Cronbach’s alfa) and test-test reliability (inter-
class correlation coefficient). Then a 2x3 univariate analysis of 
variance (ANOVA) was carried out to assess group and time 
differences as well as group by time interactions, i.e. group 
differences depending on time.
All analyses were carried out in SPSS v 11.0
E T H I C A L  C O N S I D E R A T I O N S
The study protocol was approved by the Ethics Committee 
of our hospital.
Patients participating in the study were asked to complete 
a written consent after having been fully informed about the 
nature and the aims of the study.
R E S U L T S
Between September 2003 and March 2004, 50 patients 
were equally randomized in group A and group B. Their clini-
cal and laboratory characteristics are shown in table 3. Sex, 
age, stage and PS did not differ significantly in the two groups. 
Mean Hb was 9.81 gr/dl ± 1.02 (±SD) in group A and 10.2 
gr/dl ± 0.87 (±SD) in group B (p=NS). Mean serum ferritin 
level was 202 ng/ml ± 142 (±SD) in group A and 390 ng/ml 
± 551 (±SD) in group B (p=NS).
1 .  H A E M O G L O B I N  R E S P O N S E :
Total Response (TR) and Complete Response (CR) rates 
after 4 and 8 weeks of erythropoetic treatment are separately 
shown for Darbepoetin alfa and Epoetin in table 4. At 4 weeks, 
TABLE 2. Detailed pre-randomisation tests and follow-up investigations
Pre-randomisation tests                                                                                    Follow-up tests
1. Complete blood count and review of peripheral blood smear                         1. Complete blood count was performed before each
2. Serum creatinine                                                                                                   course of chemotherapy and in weeks 4 and 8
3. Serum Folate level and B12 level                                                                         2. Serum iron level was estimated every 3 weeks
4. Serum iron level and ferritin concentration                                                      3. Serum ferritin was estimated every 3 weeks
5. Serum LDH, bilirubin and reticulocyte count for evidence of haemolysis
6. Bone marrow examination if there was a suspicion of tumour infiltration
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TABLE 5. Changes in haemoglobin level for group A, group B and for all 50 patients.
Timing              Group A  Group B  Whole Group
                         Mean Hb (SD)  Mean Hb (SD)  Mean HB (SD)
 baseline            9.8 (1.04)  10.2 (.87)  10.02 (.87)
                         p=.007  p=.075  p=.003
 week 4             p=.001 10.6 (1.4) p=.005 10.8 (1.9) p=.000 10.75 (1.69)
                         p=.011  p=.080  p=.003
 week 8              11.4 (1.99)  11.6 (2.3)  11.5 (2.12)
TABLE 3. Clinical and laboratory characteristics of the 50 
eligible patients included in the study.
Characteristics rHuEPO Darbepoetin
       No (%) No (%)
Age (years) 61 65
median (range) (44-76) (47-76)
Sex (Female) 11 (22) 12 (20)
Disease
   Breast 2 (8) 1 (4)
   colon 6 (24) 5 (10)
   lung 14 (56) 9 (36)
   ovarian 1 (4) 5 (20)
   stomach 2 (8) 1 (4)
   various – 4 (16)
Stage 
   II – 2 (4)
   III 6 (24) 9 (36)
   IV 19 (76) 14 (56)
ECOG
   0 - 1 17 (68) 13 (52)
   2 7 (28) 9 (36)
   3 1 (4) 3 (12)
Haemoglobin (g%)
   Mean ±SD 9,81 ± 1,02 10.2 ± 0,87
Ferritin (ng/ml)
      Mean ±SD 202 ± 142 390± 551
TABLE 4. Haemoglobin response rate to haemopoetic therapy.
Type of response  Week 4   Week 8  Total
 Group A  Group B Group A  Group B
 N (%)  N (%) N (%)  N (%)
Complete response 7 (28)  8 (32) 11 (44)  11 (44) 22 (44)
  (p=NS)   (p=NS)
Partial response 4 (16)  3 (12) 1 (4)  4 (16) 5 (10)
  (p=NS)   (p=NS)
Total response 11 (44)  11 (44) 12 (48)  15 (60) 27 (54)
  (p=NS)   (p=NS)
Darbepoetin alfa.
In 7 out of 14 (50%) responding patients, Epoetin dose 
had to be doubled as opposed to 7 out of 15 (47%) responders 
with Darbepoetin alfa (p=NS).
The needs for blood transfusion were similar in both 
groups (12% in group A versus 16% in group B). 
2 .  C H A N G E S  I N  H E M O G L O B I N  L E V E L  O N  W E E K  
4  A N D  W E E K  8 :
Changes in Hb level during the study period for each group 
of patients, as well as for all 50 patients, are shown in table 
5. For group A, there was a significant increase in mean Hb 
both at 4 and 8 weeks (p=.007 and p=.001, respectively). A 
significant increase (p=.011) was also observed between weeks 
4 and 8. For group B, the increase in Hb level was significant 
(p=.005) in week 8, but not in week 4 (p=.075). Similarly, 
no significant (p=.08) increase was observed between weeks 
4 and 8.
During the study period, 2 out of the 25 (8%) patients 
on Epoetin and 9 out of the 25 (36%) on Darbepoetin alfa 
achieved the Hb level of 13.5 g/dl (p=.017), the predefined 
point for dose titration. 
For the whole group of 50 patients, mean Hb level in-
creased significantly after 4 and 8 weeks of treatment (p=.003 
and p=.000, respectively). A significant increase (p=.003) was 
also observed between week 4 and week 8.
3 .  Q U A L I T Y  O F  L I F E :
Statistical analysis of the QoL findings demonstrated 
high internal consistency for FACT-G. There was also 
high degree of test-retest reliability for physical and social 
there was an identical TR rate in both groups of patients and 
a higher but not significant (p=NS) CR with Darbepoetin 
alfa. At week 8, CR rate was identical for both Epoetin and 
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well-being, emotional well-being and functional well-being. 
Regarding the fatigue subscale (11 items), there was high 
internal consistency as well as high test-retest reliability. The 
additional non-fatigue subscale showed also good stability but 
low internal consistency. 
Physical well-being: There were no significant (p=.21) dif-
ferences in mean physical well-being score over time between 
the two groups. The observed differences were constant over 
time (p=.62 for time by group interaction), indicating that 
groups do not differ significantly over the three assessments 
(Figure 1). 
Social well-being: There were no significant (p=.49) dif-
ferences in mean social well-being score over time between 
the two groups, and those differences that were observed 
were constant over time (p=.99 for group by time interac-
tion, Figure 2).
Functional well-being: Mean functional well-being score by 
group over time is shown in figure 3. There were no significant 
differences in mean functional score between the two groups 
(p=.53) and the observed differences were constant over time 
(p=.57 for time by group interaction).
Emotional well-being: There were significant differences 
in mean emotional well-being score between the two groups 
(p=.016) in favour of group A. Patients in group B had a ten-
dency for increased emotional scores over time compared with 
group A (p=.08 for time by group interaction), indicating that 
patients in group B are getting worse over time (Figure 4).
Fatigue subscale: There were significant differences in 
mean fatigue score between the two groups (p=.001), with 
those in group B having higher fatigue scores than those in 
FIGURE 1. Changes in mean physical well-being score during 
therapy with rHuEPO and Darbepoetin, respectively.
FIGURE 3. Changes in mean functional well-being score during 
therapy with rHuEPO and Darbepoetin, respectively.
FIGURE 2. Changes in mean social well-being score during 
therapy with rHuEPO and Darbepoetin, respectively.
FIGURE 4. Changes in mean emotional well-being score during 
therapy with rHuEPO and Darbepoetin, respectively.
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FIGURE 5. Changes in mean fatigue score during therapy with 
rHuEPO and Darbepoetin, respectively.
FIGURE 6. Changes in mean non-fatigue score during therapy 
with rHuEPO and Darbepoetin, respectively.
has been recently adopted by many oncologists [15,16,18], a 
head to head comparative study of this schedule with TIW 
Epoetin has not been published so far. From this point of view, 
we consider that the publication of our findings, although still 
based on a rather small number of patients, is warranted. The 
two groups of patients we studied are well defined, doses and 
schedules of Epoetin and Darbepoetin alfa are those recom-
mended in clinical practice and, most importantly, the assess-
ment of the impact of the erythropoetins on the quality of life 
of the patients is based on the completion of the FACT-An 
questionnaire by an exceptional 96% of patients at baseline, 
98% at week 4 and 97% at week 8 of treatment.
We found that, on the whole, the administration of eryth-
ropoietic treatment was associated with a significant increase 
in Hb level after 4 weeks of treatment and a highly significant 
increase after 8 weeks. A significant increase was also ob-
served between week 4 and 8. Nevertheless, when the results 
were analysed separately for the two groups of patients, the 
increase remained highly significant after 8 weeks for both 
erythropoetins but it was significant only for Epoetin after 4 
weeks. Likewise, the observed increase in Hb level between 
week 4 and week 8 was significant only for Epoetin.
On the other hand, TR, PR or CR rates were not sig-
nificantly different between Epoetin and Darbepoetin alfa 
at neither 4 nor 8 weeks although, after 8 weeks, there was 
a trend in favor of Darbepoetin alfa in terms of PR (16% 
versus 4%) and TR (60% versus 48%). Likewise, during the 
8 weeks period, a significantly higher proportion of patients 
on Darbepoetin alfa (36% versus 8%) reached the predefined 
titration cut point of 13.5g/dl.
In order to achieve a response, almost half of the patients 
in each group had to double the dose of erythropoetin during 
the study period.
Despite the observed significant increase in Hb level, 
erythropoietic therapy did not obviate the needs for blood 
transfusion which proved to be similar in both groups of pa-
tients. It is worth noting that the 16% requirement for transfu-
sions with the use of Darbepoetin alfa observed in our study is 
considerably lower than the 27% observed by others [19].
The impact of erythropoietic treatment on the quality 
of life in terms of physical, social and functional well-being 
score did not differ between the two groups. Furthermore, the 
observed, non-significant, differences were similar over time. 
However, there were significant differences in mean emotional 
score between the two groups with patients in Darbepoetin 
alfa group showing a tendency for increased emotional scores 
over time, indicating that they are getting worse over time. In 
addition to emotional well-being, there were also significant 
differences in mean fatigue score between the two groups 
with those on Darbepoetin alfa having higher fatigue scores, 
indicating that they are doing worse than patients on Epoetin. 
It is not easy to explain this rather unexpected observation. 
It might be due to the more significant increase in mean Hb 
group A, indicating that the former group was doing worse 
than the latter (Figure 5). 
Non-fatigue subscale: There were no significant differences 
in mean non-fatigue score between the two groups (p=.49) 
and the observed differences were similar over time (p=.89 
for time by group interaction, Figure 6).
D I S C U S S I O N
Although it is considered that QW Darbepoetin alfa is 
effective for cancer related anaemia [12-14] and this practice 
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at week 4 observed with Epoetin or it might be the play of 
chance because of the small number of patients. Finally, in 
terms of non-fatigue score the two groups demonstrated 
similar behaviour.
We observed no serious adverse reactions with either drug 
and local pain at the site of injection was not a problem with 
either Epoetin or Darbepoetin alfa.
C O N C L U S I O N S
With due caution, because of the small number of pa-
tients studied, we conclude that once weekly Darbepoetin alfa 
seems to be equally effective in ameliorating chemotherapy 
induced anaemia as thrice weekly Epoetin. However, whether 
its observed inferiority in terms of fatigue and emotional well-
being is an incidental finding and to what degree this would 
counteract its more convenient administration schedule is not 
easy to assess at the moment.
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